Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162843000> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3162843000 endingPage "2029" @default.
- W3162843000 startingPage "2029" @default.
- W3162843000 abstract "2029 Background: Lutathera’s ( Lu-177 DOTATATE) FDA approval in 2018 in the United States for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) including foregut, midgut and hindgut neuroendocrine tumors in adults, ushered in a welcome change in the field the modern practice of theranostics. The deployment of lutathera and other similar PRRT therapies in any hospital or outpatient setting comes with its own challenges. Not many centers in the country are equipped to handle the treatment logistics including but not limited to having dedicated treatment areas, knowledgeable staff trained and equipped to handle the treatment and radiation safety contingency plans. For non-FDA approved indications, the ordeals hurdles are even larger and more complex. There are quite a few non-neuroendocrine indications not in the FDA label that Lutathera has shown promise in small cohorts outside the US. Such indications include: 1. Paragangliomas/pheochromocytomas. 2. Esthesioneuroblastomas/olfactory neuroblastomas. 3. Thymic and Pulmonary NET 4. Pediatric Neuroblastomas. 5. Intractable meningiomas refractory to conventional therapies such as multiple surgical resections and stereotactic radiation. In this educational exhibit, we examine pertinent cases and the benefits, pertinent case review, challenges, and opportunities for the nuclear medicine theranostician while dealing with matters of such off-label indications. Objectives: To review the off-label indications of Lutathera vs the conventional standard of care for such rare indications. To examine some pertinent cases performed in our academic center and their unique circumstances that made such patients qualify for the lutathera option. To study the challenges faced by the theranostic team to get the third-party payor approval, review step-by-step approaches such as the peer review process with the insurance companies to accomplish the authorization and approval. To evaluate the role of the theranostician (nuclear medicine or the theranostic team leader) in orchestrating the team-play amongst the referring physicians/ oncologists, tumor boards, the lutathera treatment center, P&T pharmacy & therapeutics committee, hospital administration, and the third-party payors." @default.
- W3162843000 created "2021-05-24" @default.
- W3162843000 creator A5005966586 @default.
- W3162843000 creator A5008016353 @default.
- W3162843000 creator A5017848559 @default.
- W3162843000 creator A5043449867 @default.
- W3162843000 creator A5068166337 @default.
- W3162843000 creator A5073785005 @default.
- W3162843000 creator A5083812473 @default.
- W3162843000 creator A5091053515 @default.
- W3162843000 date "2021-05-01" @default.
- W3162843000 modified "2023-09-27" @default.
- W3162843000 title "Off-label usage of Lu-177 DOTATATE therapy : Challenges and Opportunities for the Theranostician" @default.
- W3162843000 hasPublicationYear "2021" @default.
- W3162843000 type Work @default.
- W3162843000 sameAs 3162843000 @default.
- W3162843000 citedByCount "0" @default.
- W3162843000 crossrefType "journal-article" @default.
- W3162843000 hasAuthorship W3162843000A5005966586 @default.
- W3162843000 hasAuthorship W3162843000A5008016353 @default.
- W3162843000 hasAuthorship W3162843000A5017848559 @default.
- W3162843000 hasAuthorship W3162843000A5043449867 @default.
- W3162843000 hasAuthorship W3162843000A5068166337 @default.
- W3162843000 hasAuthorship W3162843000A5073785005 @default.
- W3162843000 hasAuthorship W3162843000A5083812473 @default.
- W3162843000 hasAuthorship W3162843000A5091053515 @default.
- W3162843000 hasConcept C105702510 @default.
- W3162843000 hasConcept C126322002 @default.
- W3162843000 hasConcept C170774537 @default.
- W3162843000 hasConcept C177713679 @default.
- W3162843000 hasConcept C19527891 @default.
- W3162843000 hasConcept C2779066768 @default.
- W3162843000 hasConcept C2993559085 @default.
- W3162843000 hasConcept C61434518 @default.
- W3162843000 hasConcept C71924100 @default.
- W3162843000 hasConceptScore W3162843000C105702510 @default.
- W3162843000 hasConceptScore W3162843000C126322002 @default.
- W3162843000 hasConceptScore W3162843000C170774537 @default.
- W3162843000 hasConceptScore W3162843000C177713679 @default.
- W3162843000 hasConceptScore W3162843000C19527891 @default.
- W3162843000 hasConceptScore W3162843000C2779066768 @default.
- W3162843000 hasConceptScore W3162843000C2993559085 @default.
- W3162843000 hasConceptScore W3162843000C61434518 @default.
- W3162843000 hasConceptScore W3162843000C71924100 @default.
- W3162843000 hasLocation W31628430001 @default.
- W3162843000 hasOpenAccess W3162843000 @default.
- W3162843000 hasPrimaryLocation W31628430001 @default.
- W3162843000 hasRelatedWork W1010160327 @default.
- W3162843000 hasRelatedWork W1482826844 @default.
- W3162843000 hasRelatedWork W1798762987 @default.
- W3162843000 hasRelatedWork W1981570883 @default.
- W3162843000 hasRelatedWork W1985569278 @default.
- W3162843000 hasRelatedWork W1992516817 @default.
- W3162843000 hasRelatedWork W2012745681 @default.
- W3162843000 hasRelatedWork W2047973387 @default.
- W3162843000 hasRelatedWork W2077845644 @default.
- W3162843000 hasRelatedWork W2096220058 @default.
- W3162843000 hasRelatedWork W2151554756 @default.
- W3162843000 hasRelatedWork W2204938309 @default.
- W3162843000 hasRelatedWork W2267025725 @default.
- W3162843000 hasRelatedWork W2343647968 @default.
- W3162843000 hasRelatedWork W2401868934 @default.
- W3162843000 hasRelatedWork W2921008951 @default.
- W3162843000 hasRelatedWork W2980080817 @default.
- W3162843000 hasRelatedWork W3004447213 @default.
- W3162843000 hasRelatedWork W3120311828 @default.
- W3162843000 hasRelatedWork W3196364186 @default.
- W3162843000 hasVolume "62" @default.
- W3162843000 isParatext "false" @default.
- W3162843000 isRetracted "false" @default.
- W3162843000 magId "3162843000" @default.
- W3162843000 workType "article" @default.